Cladis Investment Advisory’s Catalyst Pharmaceutical CPRX Stock Holding History

Cladis Investment Advisory’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$248K	Hold	10,020	–	–	0.14%	136
2025 Q4	$234K	Buy	+10,020	New	+$223K	0.13%	143
2025 Q3	–	Sell	-10,000	Closed	-$217K	–	149
2025 Q2	$217K	Hold	10,000	–	–	0.14%	129
2025 Q1	$243K	Hold	10,000	–	–	0.18%	111
2024 Q4	$209K	Hold	10,000	–	–	0.15%	121
2024 Q3	$199K	Hold	10,000	–	–	0.14%	128
2024 Q2	$155K	Buy	+10,000	New	+$156K	0.11%	130
2024 Q1	–	Sell	-10,000	Closed	-$168K	–	142
2023 Q4	$168K	Hold	10,000	–	–	0.13%	134
2023 Q3	$117K	Hold	10,000	–	–	0.1%	124
2023 Q2	$134K	Hold	10,000	–	–	0.12%	129
2023 Q1	$166K	Hold	10,000	–	–	0.15%	131
2022 Q4	$186K	Hold	10,000	–	–	0.19%	124
2022 Q3	$128K	Hold	10,000	–	–	0.14%	120
2022 Q2	$70.1K	Hold	10,000	–	–	0.07%	129
2022 Q1	$82.9K	Hold	10,000	–	–	0.07%	146
2021 Q4	$67.7K	Buy	+10,000	New	+$65.8K	0.05%	144

Other funds holding CPRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Cladis Investment Advisory's CPRX Position: Q1 2026 in Review

Cladis Investment Advisory held its Catalyst Pharmaceutical (CPRX) position steady in Q1 2026 at 10,020 shares worth $248K. The position accounts for 0.14% of the portfolio, ranked #136.

Cladis Investment Advisory first reported a position in CPRX in Q4 2021 and has held it in 16 quarters since. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

Cladis Investment Advisory held 10,020 shares of Catalyst Pharmaceutical worth $248K as of Q1 2026.
Cladis Investment Advisory left its Catalyst Pharmaceutical share count unchanged in Q1 2026.
Catalyst Pharmaceutical made up 0.14% of Cladis Investment Advisory's portfolio in Q1 2026, its #136 holding.
Cladis Investment Advisory first reported a position in Catalyst Pharmaceutical in Q4 2021 and has held it in 16 quarters since.
380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on Cladis Investment Advisory's 13F filing for Q1 2026, filed 15 May 2026.